USPTO serial 87699921
Z ZACOL NMX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CALLAGHAN, BRIAN P
- Law office
- TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with Z ZACOL NMX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Pickerill
JOHN PICKERILL FREDRIKSON & BYRON, P.A.200 S. 6TH STREETSUITE 4000MINNEAPOLIS, MN 55402Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for intestinal disorders; pharmaceutical preparations for use in gastroenterology, for the prevention and treatment of diarrhea, antibiotic-associated diarrhea, travellers' diarrhea, for colon and digestive system health and regulation, for improving energy levels, and for maintaining and improving mucous levels and the mucosal lining of the intestines and colon; pharmaceutical preparations for use in sanitary preparations for medical purposes, namely, nutraceutical preparations for colon and digestive system health and regulation, for maintenance and improvement of energy levels, and for maintaining and improving mucous levels and the mucosal lining of the intestines and colon; pharmaceutical preparations for stimulating the growth of intestinal flora, restoring energy and metabolism of the colocyte and rescuing of the colonic mucosal trophism; pharmaceutical preparations for the treatment of colon disorders; pharmaceutical preparations for improving epithelial vitality and repair; pharmaceutical preparations for the prevention or treatment of cancer; pharmaceutical preparations for the prevention or treatment of colorectal cancer; pharmaceutical preparations for restoring the metabolic balance; pharmaceutical preparations for improving the trophic conditions of the mucosa; pharmaceutical preparations for regulating human gut homeostasis; pharmaceutical preparations for the treatment of gastro-intestinal disorders; pharmaceutical preparations for the treatment of inflammatory bowel disease, motility and functional disorders of the bowel such as IBS and colorectal tumours; pharmaceutical preparations for the maintenance of colon eubiosis; pharmaceutical preparations for decreasing intestinal inflammation; pharmaceutical preparations for promoting, supporting and maintaining a healthy colon; pharmaceutical preparations for the treatment of colitis, ulcerative colitis, Crohn's disease, radiation colitis, pouchitis, infectious colitis and shigellosis; pharmaceutical preparations for the treatment of polyposis of the colon; pharmaceutical preparations for the treatment of pain; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical and veterinary preparations in the form of tablets, capsules, sugar-coated pills, granules, powders or suppositories for use in treating gastrointestinal diseases and conditions; Pharmaceutical preparations, namely, anti-flatulars; sanitary preparations for medical purposes; dietetic foods adapted for medical use; dietetic beverages and food adapted for medical use; pharmaceutical preparations for the treatment of the intestinal infections; pharmaceutical preparations used to treat gastro-intestinal diseases and conditions, diagnostic agents, preparations and substances related to the gastro-intestinal field for medical purposes; medical preparation based on butyric acid and inulin that contributes to the restoration of intestinal barrier; lactic ferments for pharmaceutical use; biological preparations for use in the gastrointestinal diseases and conditions; food supplements; dietary supplements; vitamin supplements; nutritional supplements; dietary supplemental drinks; vitamin preparations in the form of food supplements; nutraceutical products for use as dietary supplements; Nutraceutical preparations for therapeutic or medical purposes; Mineral supplements for human use | ACTIVE | — |
| 010 | Medical apparatus for introducing pharmaceutical preparations, food supplements and nutraceuticals into the human body; Medical apparatus for introducing pharmaceutical preparations, food supplements and nutraceuticals into the colon; Enema apparatus; Enema syringes; Enema apparatus for medical purposes; Medical apparatus for introducing enema preparations into the human body; Injection syringes; Syringes for medical purposes; Surgical devices and instruments; Disposable syringes; Medical device for use in diagnosis and treatment of the gastro-intestinal tract | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 8, 2019 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 8, 2019 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 10, 2018 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 10, 2018 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 10, 2018 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 13, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 13, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 14, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 12, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 9, 2017 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Dec 8, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 1, 2017 | NWAP | NEW APPLICATION ENTERED | — |